ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
39 hedge funds and large institutions have $3.48M invested in ImmunoCellular Therapeutics, Ltd. in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 37 → 39 (+2)
16% less call options, than puts
Call options by funds: $789K | Put options by funds: $938K
60% less capital invested
Capital invested by funds: $8.67M → $3.48M (-$5.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$329K |
| 2 |
D.E. Shaw & Co
New York
|
+$286K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
+$284K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$273K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$508K |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$318K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$249K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$178K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$94.4K |
IMUC Hedge Fund Activity: Q4 2013 in Review
39 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q4 2013, worth a combined $3.48M — down 60% from $8.67M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMUC positions and 6 closed out — a net gain of 2 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $329K. The largest seller was Goldman Sachs, cutting an estimated $508K.
- 39 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q4 2013, up from 37 in Q3 2013.
- Funds reported $3.48M of ImmunoCellular Therapeutics, Ltd. stock for Q4 2013, down 60% quarter-over-quarter.
- 8 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q4 2013 and 6 closed out, a net change of +2 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q4 2013 was Credit Suisse, an estimated $329K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q4 2013 was Goldman Sachs, an estimated $508K sold.
Based on aggregated 13F filings for Q4 2013.